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Dynamic alterations in decoy VEGF receptor-1
stability regulate angiogenesis
Joshua M. Boucher1,2,w, Ryan P. Clark1, Diana C. Chong3, Kathryn M. Citrin1, Lyndsay A. Wylie3
& Victoria L. Bautch1,2,3,4
Blood vessel expansion is driven by sprouting angiogenesis of endothelial cells, and is
essential for development, wound healing and disease. Membrane-localized vascular
endothelial growth factor receptor-1 (mVEGFR1) is an endothelial cell-intrinsic decoy receptor
that negatively modulates blood vessel morphogenesis. Here we show that dynamic
regulation of mVEGFR1 stability and turnover in blood vessels impacts angiogenesis.
mVEGFR1 is highly stable and constitutively internalizes from the plasma membrane.
Post-translational palmitoylation of mVEGFR1 is a binary stabilization switch, and ligand
engagement leads to depalmitoylation and lysosomal degradation. Trafficking of palmitoyla-
tion enzymes via Rab27a regulates mVEGFR1 stability, as reduced levels of Rab27a impaired
palmitoylation of mVEGFR1, decreased its stability, and elevated blood vessel sprouting and
in vivo angiogenesis. These findings identify a regulatory axis affecting blood vessel
morphogenesis that highlights exquisite post-translational regulation of mVEGFR1 in its role
as a molecular rheostat.
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N
ew blood vessel formation from existing vessels via
endothelial cell sprouting is called angiogenesis, and enables
vessels to dynamically respond to tissue requirements for
oxygen and nutrients1–3. Vascular Endothelial Growth Factor-A
(VEGF-A)-mediated signalling is crucial for angiogenesis4,5. Local
production of VEGF-A stimulates angiogenesis upon binding to
endothelial cell-expressed vascular endothelial growth factor
receptor-2 (VEGFR2)6. Tight control of VEGF-A signalling is
required for proper vessel growth and patterning, and increased
VEGF-A signalling is linked to disease7,8.
A second vascular endothelial growth factor receptor, VEGFR1,
is alternatively spliced to yield both soluble (sVEGFR1) and
membrane-tethered (mVEGFR1) isoforms9. Both isoforms bind
VEGF-A with tenfold higher affinity than VEGFR2, but mVEGFR1
has weak kinase activity in endothelial cells and signalling appears
confined to pathological situations10–14. Signalling through
mVEGFR1 is also important in bone-marrow-derived cells such
as macrophages for homing to sites of inflammation and
ischaemia15,16. Two other ligands, VEGF-B and platelet-derived
growth factor (PLGF), bind exclusively to VEGFR1; VEGF-B
binding does not lead to detectable signalling, whereas PLGF
binding can produce a signal17,18. Mice genetically lacking
VEGFR1 (Flt-1 in the mouse) die prenatally from overgrown
blood vessels19, but mice lacking the signalling domain of mFlt-1
are viable and fertile20, indicating that mVEGFR1 signalling is
not required for vascular development. Genetic rescue of either
mFlt-1 or sFlt-1 reduces VEGFR2 signalling and mitigates the
overgrowth of embryonic stem cell-derived Flt-1 / mutant
vessels21, supporting that both VEGFR1 isoforms function as
molecular rheostats to negatively modulate VEGFR2 signalling
during developmental angiogenesis.
Although the consequences of VEGFR1 loss are well-
documented, how mVEGFR1 availability is controlled to
modulate signalling is unknown. Post-translational modifications
diversify protein function and specify localization and turnover22.
Post-translational regulation of VEGFR2 is well-characterized;
for example, phosphorylation and ubiquitination are important
for signalling23–25. However, little is known about how
mVEGFR1 is regulated post-translationally. It was reported
that mVEGFR1 is largely Golgi-resident in cultured cells, that it
does not recycle, and that ligand-bound mVEGFR1 is
ubiquitinated and degraded26–28. It is unknown whether
VEGFR1 post-translational modifications regulate VEGF
signalling amplitude. One lipid post-translational modification,
palmitic acid addition to cysteines, or palmitoylation, is unique in
that it is reversible, thereby enabling dynamic regulation of
protein stability29. eNOS palmitoylation influences vascular
homeostasis30, and PECAM-1 palmitoylation promotes cell
surface localization in endothelial cells31. In other cell types,
palmitoylation prevents Fas receptor degradation32, regulates
ligand binding and signalling of EGFR33,34, and controls
intracellular trafficking and stability of c-MET35.
Here we show that mVEGFR1 is unusually stable and
undergoes constitutive internalization in endothelial cells.
Palmitoylation acts as a binary switch to regulate mVEGFR1
stability and trafficking via the palmitoylating enzyme DHHC3
and the depalmitoylating enzyme APT1. We identify the small
GTPase Rab27a as an upstream regulator of mVEGFR1
palmitoylation. Rab27a loss impairs mVEGFR1 palmitoylation,
increases mVEGFR1 trafficking to lysosomes for degradation and
perturbs vascular morphogenesis in vitro and in vivo. These
findings identify a unique angiogenic regulatory axis centred on
post-translational regulation of mVEGFR1 that is consistent with
its role as a molecular rheostat for VEGF-A signalling, and show
that post-translational regulation of a decoy receptor affects
biological outputs.
Results
mVEGFR1 is stable and constitutively cycles. Because
mVEGFR1 and VEGFR2 have distinct functions in VEGF-A sig-
nalling, we hypothesized that they have differential post-transla-
tional stability. We validated an antibody that recognizes both
human and mouse VEGFR1 (FLT-1) using wild-type and Flt-1 /
 mouse ES cells, and detected a band at 180 kD in wild-type but
not mutant ES cells (Supplementary Fig. 1a), indicating specific
detection of mVEGFR1. We next assessed baseline turnover of
mVEGFR1 and VEGFR2 using primary human umbilical vein
endothelial cells (HUVEC) cultured with cycloheximide (CHX) to
inhibit new protein synthesis. A dose-response analysis revealed no
loss of mVEGFR1 while VEGFR2 was undetectable at all doses
(Fig. 1a). A time course using 0.5mgml 1 of CHX showed that
VEGFR2 was undetectable after 2 h of CHX treatment (Fig. 1b),
consistent with a reported half-life of 70min (ref. 36). Surprisingly,
mVEGFR1 was not reduced with time, even after 28h, in either
HUVEC or another human endothelial cell, HBMVEC (human
brain microvascular endothelial cells) (Fig. 1b,c). We verified
VEGFR1 baseline stability by quantitative immunofluorescence,
which does not distinguish VEGFR1 isoforms, but nevertheless
showed no significant reduction in VEGFR1 signal over 24h
(Supplementary Fig. 1b). These findings indicate that mVEGFR1
turns over very slowly (half-life 428h) in relation to VEGFR2 in
endothelial cells.
We utilized a 3D sprouting angiogenesis assay to test VEGFR1/2
turnover in a more physiologically relevant setting37. Endothelial
cells sprout from beads embedded in fibrin to form polarized
sprouts with patent lumens over a 6-day period. HUVEC sprouts
treated with CHX for 18h had no detectable VEGFR2 staining, but
about half of the VEGFR1 signal remained (Fig. 1d,e), suggesting
that VEGFR1 is significantly more stable than VEGFR2 in
3D sprouts. Taken together, the two receptors have very different
turnover kinetics, consistent with their different roles in
modulating VEGF-A signalling and angiogenesis.
We next investigated the trafficking of mVEGFR1, and asked
whether the receptor reaches the cell surface and constitutively
internalizes from the surface. HUVEC were incubated with an
N-terminal-specific antibody to VEGFR1 and either the dynamin
inhibitor dynasore to block internalization, or the VEGFR1-
specific-ligand PLGF to promote internalization. Immunofluores-
cence revealed localized puncta of VEGFR1 that were dynamin-
dependent (Fig. 1f). These results suggest that VEGFR1 resides at
the cell surface and constitutively internalizes, perhaps via clathrin-
coated pits, although other routes cannot be ruled out. The
VEGFR1 puncta were also observed in PLGF-stimulated HUVEC,
consistent with ligand-stimulated internalization. We confirmed
that VEGFR1 was surface labelled and internalized by stripping
surface-bound antibodies after allowing for internalization38.
VEGFR1 puncta formed at 37 C were resistant to the stripping
protocol, while cells held at 4 C to block internalization were
sensitive to stripping (Supplementary Fig. 1c,d), indicating surface
localization and constitutive internalization.
Early endosomes sort internalized cargo for recycling or
degradation, and proteins typically recycle from endosomes to
the cell surface in a Rab4a-dependent (fast) or Rab11a-dependent
(slow) manner39. To distinguish these possibilities, we disrupted
recycling via siRNA-mediated knockdown of Rabs in HUVEC.
mVEGFR1 turnover was unaffected in control and Rab4 knock-
down endothelial cells with new protein synthesis inhibited,
while about 70% of mVEGFR1 was lost with Rab11a knock-
down (Supplementary Fig. 1e, Fig. 1g). Immunofluorescence
showed that 90% of the VEGFR1 signal was lost with
Rab11a knockdown (Fig. 1h,i). Taken together, these results
indicate that mVEGFR1 constitutively internalizes and suggest
Rab11a-dependent recycling to the plasma membrane, which is
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Figure 1 | mVEGFR1 is stable and constitutively internalizes in endothelial cells. (a) Immunoblot of HUVEC treated as indicated for 8 h; CHX,
cycloheximide; three replicates. (b) Immunoblot of HUVEC treated as indicated; three replicates. (c) Immunoblot of HUVEC or HBMVEC with indicated
treatments; two replicates. (d,e) (d) Immunofluorescence for VEGFR1 or VEGFR2 in HUVEC angiogenic sprouts with indicated treatments, scale bar:
100mm. (e) Quantification of fluorescence via integrated density. (VEGFR1 n¼ 18 sprouts per condition; VEGFR2, n¼ 25 sprouts per condition); three
replicates. (f) VEGFR1 immunofluorescence of HUVEC with indicated treatments; three replicates, scale bar: 20mm. (g) Immunoblot of HUVEC at 48 h
post-knockdown (KD) with indicated treatments; two replicates. (h,i) (h) VEGFR1 immunofluorescence of HUVEC 24 h post KD with indicated treatments,
scale bar: 20mm. (i) Quantification of fluorescence via integrated density. (No. of cells: ntRNA/H2O, n¼ 22; ntRNA/CHX, n¼ 23; siRab11a/H2O, n¼ 19;
siRab11a/CHX, n¼ 14); three replicates. Statistics: Shown are means þ95% CI. One-way ANOVA with pairwise comparison and post-hoc Tukey’s range
test. *Pr0.05; **Pr0.01; NS, not significant.
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consistent with its long half-life and non-signalling function
during vascular sprouting.
Palmitoylation dynamically regulates VEGFR1 stability.
Palmitoylation dynamically regulates protein trafficking and
turnover29. Thus, we hypothesized that palmitoylation regulates
VEGFR1 stability. Since mVEGFR1 has several potential
palmitoylation sites based on PalmPred palmitoylation40 and CSS
Palm 2.0 (ref. 41) prediction algorithms, we determined effects of
manipulating palmitoylation on baseline turnover of mVEGFR1 by
inhibiting palmitoylating enzymes (protein acetyl-transferases)
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with 2-bromohexadecadnoic acid (2-BH). Palmitoylation blockade
in HUVEC caused rapid turnover of VEGFR1 upon blockade
of new protein synthesis (Fig. 2a,b), and immunoblot confirmed
the membrane-bound VEGFR1 isoform was affected (Fig. 2c),
suggesting that palmitoylation stabilizes mVEGFR1. Similarly,
2-BH-induced palmitoylation blockade significantly decreased
baseline stability of VEGFR1 in angiogenic sprouts (Fig. 2d,e),
and levels were rescued by inhibiting the lysosome with
chloroquine in angiogenic sprouts (Supplementary Fig. 2a,b),
implying that palmitoylation stabilizes mVEGFR1 by preventing
its lysosomal degradation.
Ligand-bound VEGFR1 is internalized and degraded26.
Incubation of HUVEC with VEGF-A or PLGF led to significant
loss of mVEGFR1, although PLGF incubation reduced
VEGFR1 levels more quickly than did VEGF-A (Fig. 2f,g).
PLGF-induced degradation of mVEGFR1 was blocked by
inclusion of chloroquine, but not the proteasome inhibitor
MG132 (Supplementary Fig. 2c,d), demonstrating that PLGF
binding promotes lysosomal degradation of mVEGFR1. PLGF- or
VEGF-A-induced loss of mVEGFR1 was blocked by Palmostatin-
B (Pal-B), an inhibitor of depalmitoylating enzymes (acyl-protein
thioesterases, APTs) (Fig. 2h,i). We also found that blockade of
depalmitoylation prevented ligand-induced loss of VEGFR1
in angiogenic spouts (Fig. 2j,k), consistent with the 2D data.
Collectively, these results show that palmitoylation regulates
the stability and ligand-induced turnover of mVEGFR1 in
endothelial cells and angiogenic sprouts.
mVEGFR1 palmitoylation regulates trafficking. To determine
the effects of VEGFR1 palmitoylation on its trafficking, we
examined localization under conditions of impaired activity. We
first examined the co-localization of an endothelial cell surface
marker, PECAM-1 (PECAM) with VEGFR1. There was
measurable overlap at baseline, consistent with the idea that some
mVEGFR1 is cell-surface localized, and this overlap was
significantly reduced upon blockade of palmitoylation with 2-BH
(Fig. 3a,c). Immunoblot analysis after cell surface biotinylation
confirmed that blockade of palmitoylation reduced cell surface-
localized mVEGFR1 and increased its intracellular location,
consistent with palmitoylation being involved in residence of
mVEGFR1 at the cell surface (Fig. 3d). We next examined
the co-localization of VEGFR1 and Rab11a and found
that overlap that was significantly reduced with blockade of
palmitoylation, in line with a role for Rab11a in regulating
VEGFR1 recycling (Fig. 3b,e). Finally, we hypothesized that
blockade of palmitoylation would increase the amount of
lysosome-mediated degradation of VEGFR1, and consistent
with this idea found significantly increased co-localization of
VEGFR1 and the lysosome marker LAMP-1 upon palmitoylation
blockade (Supplementary Fig. 3a,b). These data show that
post-translational palmitoylation of mVEGFR1 likely mediates
trafficking to the cell surface and slow recycling.
mVEGFR1 palmitoylation is enzymatically regulated. To
directly assess palmitoylation of mVEGFR1 in endothelial
cells, we utilized an acyl-resin-assisted capture (Acyl-RAC)
assay42. Blockade of free cysteines, followed by hydroxylamine
(HAM)-mediated cleavage of palmitic acid and protein capture
with thiopropyl-sepharose revealed mVEGFR1 capture that was
reduced by inclusion of the palmitoylation inhibitor 2-BH relative
to controls, suggesting that mVEGFR1 is palmitoylated in
endothelial cells (Fig. 4a,b). Palmitoylation of mVEGFR1 in
endothelial cells was supported using another assay, Acyl-biotin
exchange43 (Supplementary Fig. 4a,b). We next hypothesized that
depalmitoylation of mVEGFR1 is required for ligand-induced
instability, and used the Acyl-RAC assay to reveal reduced levels
of captured mVEGFR1 upon incubation with the VEGFR1
ligands VEGF-A, VEGF-B or PLGF, relative to controls (Fig. 4c),
indicating that ligand binding reduces steady-state levels of
palmitoylated mVEGFR1.
DHHC enzymes palmitoylate and APT enzymes depalmitoy-
late proteins44,45 (Fig. 4d). Because DHHC3 is expressed and
functionally active in endothelial cells46, we hypothesized that it
regulates baseline mVEGFR1 levels. We confirmed reduced
DHHC3 protein with siRNA knockdown (Fig. 4g, Suppleme-
ntary Fig. 4c,d), and found that DHHC3 knockdown in HUVEC
significantly lowered baseline mVEGFR1 levels (Fig. 4e–g,
Supplementary Fig. 4d) and reduced mVEGFR1 captured by
the Acyl-RAC assay compared to controls, suggesting reduced
palmitoylation of the receptor (Fig. 4h). In contrast, reduction of
another palmitoylating enzyme expressed in endothelial cells,
DHHC7, did not affect mVEGFR1 levels (Supplementary Fig. 4e),
while over-expression of DHHC3 increased levels of mVEGFR1
in endothelial cells (Fig. 4i). Thus, DHHC3 regulates mVEGFR1
stability in endothelial cells, perhaps via direct palmitoylation
of mVEGFR1.
We next asked whether loss of the depalmitoylating enzyme
APT1 prevented ligand-induced degradation of mVEGFR1, and
found that APT1 knockdown along with incubation with either
VEGF-A or PLGF blocked loss of mVEGFR1 and caused
upregulation of mVEGFR1 levels, perhaps as a result of impaired
turnover (Fig. 4j,k). In contrast, APT1 knockdown did not
significantly alter VEGFR2 levels, although downregulation of
VEGFR2 with VEGF-A and upregulation with PLGF treatment
was observed, as has been reported in other systems47. We next
assessed the effects of DHHC3 knockdown on sprouting
angiogenesis, and showed increased sprouting with reduced
DHHC3 levels (Fig. 4l–n). Thus, the proximate regulators of
mVEGFR1 palmitoylation and stability in endothelial cells are
likely DHHC3 and APT1.
Figure 2 | Palmitoylation regulates mVEGFR1 stability. (a,b) (a) VEGFR1 immunofluorescence of HUVEC with indicated treatments. (b) Quantification of
fluorescence via integrated density. (No. of cells: EtOH/H2O, n¼ 20; EtOH/CHX, n¼ 12; 2-BH/H2O n¼ 24; 2-BH/CHX n¼ 18); CHX, cycloheximide; two
replicates, scale bar: 25mm. (c) Immunoblot of HUVEC with indicated treatments; four replicates. (d,e) (d) VEGFR1 immunofluorescence of d5 HUVEC
angiogenic sprouts with indicated treatments; 2-BH, 2-bromohexadecadnoic acid, scale bar: 25mm. (e) Quantification of fluorescence via integrated
density. (No. of sprouts: EtOH/H2O, n¼ 20; EtOH/CHX, n¼ 12; 2-BH/H2O, n¼ 24; 2-BH/CHX, n¼ 18); two replicates. (f) Quantification of VEGFR1
fluorescence in HUVEC with indicated treatments via integrated density. (n¼ 50 cells per condition); four replicates. (g) Immunoblot of HUVEC stimulated
with 50 ngml 1 PLGF or PBS for indicated times; four replicates. (h) Quantification of VEGFR1 fluorescence of HUVEC with indicated treatments and
50 ngml 1 PLGF or VEGF-A via integrated density. Pal-B, palmostatin-B. (No. of cells: DMSO/PBS, n¼ 51; DMSO/PLGF, n¼ 37; DMSO/VEGF-A, n¼45;
Pal-B/PBS, n¼ 50; Pal-B/PLGF n¼48; Pal-B/VEGF-A, n¼ 51); three replicates. (i) Immunoblot of HUVEC with indicated treatments and 50 ngml 1 PLGF
or VEGF-A for 1 h. Values are mVEGFR1 normalized to respective PBS controls; three replicates. (j,k) (j) VEGFR1 immunofluorescence of d5 HUVEC
angiogenic sprouts with indicated treatments and 75 ngml 1 PLGF or PBS for 4 h, scale bar: 25mm. (k) Quantification of fluorescence via integrated
density. (No. of sprouts: DMSO/PBS n¼ 13; DMSO/PLGF, n¼ 17; Pal-B/PBS n¼ 12; Pal-B/PLGF n¼ 16); two replicates. Statistics: Shown are meansþ95%
CI. One-way ANOVA with pairwise comparison and post-hoc Tukey’s range test. *Pr0.05; **Pr0.01; NS, not significant.
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Rab27a regulates DHHC3 localization and VEGFR1 stability.
To better understand regulation of VEGFR1 turnover, we
considered potential upstream regulators of DHHC3, and we
hypothesized that spatial regulation of enzyme availability
to mVEGFR1 is coordinated by Rab GTPases. Although
numerous Rab GTPases affect receptor trafficking48,49, little
is known about direct effects on stability via effects on
post-translational modifiers. Because Rab27a regulates protein
stability and trafficking50,51 and is active in endothelial cells, we
hypothesized that Rab27a regulates proper trafficking of
palmitoylation enzymes. When Rab27a levels were reduced
by knockdown in endothelial cells, DHHC3 overlap with the
Golgi marker TGN46 increased and overlap with Rab27a
decreased in the absence of reduced DHHC3 levels, consistent
with mis-trafficking (Fig. 5a,b, Supplementary Fig. 5a–c). In
contrast, reduction of Rab11a did not alter DHHC3 overlap
with TGN46, showing specificity for effects of Rab27a
knockdown and suggesting that palmitoylation is upstream
of Rab11a trafficking of mVEGFR1 (Supplementary Fig. 5d).
Based on increased localization of DHHC3 to the Golgi with
reduced Rab27a, we hypothesized that Rab27a regulates the
spatial distribution of DHHC3 in endothelial cells. Sub-cellular
fractionation showed that DHHC3 localized to the soluble
fraction and, to a lesser extent, the cytoskeletal fraction
in controls. Strikingly, DHHC3 was undetectable in the soluble
and cytoskeletal fractions in endothelial cells with reduced
Rab27a levels, but accumulated to high levels in the membrane
fraction that is also enriched for the Golgi marker GM130
(Fig. 5c). Consistent with our hypothesis, Rab27a was also
localized to the soluble and cytoskeletal fractions (Supplementary
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Fig. 5e). DHHC21, another acetyl-transferase expressed in
endothelial cells, did not follow those trends in response to
reduced Rab27a levels. These findings are consistent with a
mechanism whereby the spatial distribution of DHHC3 is
regulated by Rab27a.
These findings suggested that reduced levels of Rab27a might
destabilize mVEGFR1 as a result of impaired palmitoylation
downstream of DHHC3 mis-trafficking. Consistent with
this hypothesis, there was little overlap between Rab27a and
VEGFR1 in endothelial cells by immunofluorescence analysis
(Supplementary Fig. 5f), but substantial overlap of VEGFR1 and
DHHC3 that was significantly decreased with reduced Rab27a
levels (Supplementary Fig. 6a–c). We next assessed VEGFR1
levels in angiogenic sprouts or cultured endothelial cells after
knockdown of Rab27a or Rab3a, another protein trafficking
regulator that has some overlapping functions with Rab27a (ref.
52). VEGFR1 was significantly reduced in Rab27a knockdown
sprouts and by immunoblot, while knockdown of Rab3a did not
affect VEGFR1 levels in sprouts or by immunoblot (Fig. 5d–f,
Supplementary Fig. 6d). In contrast, VEGFR2 levels remained
unchanged in Rab27a knockdown sprouts and were marginally
elevated in immunoblots of endothelial cells (Fig. 5f, Supple-
mentary Fig. 6e,f). These results imply that Rab27a regulates
mVEGFR1 protein levels in endothelial cells. To determine the
mechanism of mVEGFR1 degradation in response to Rab27a
knockdown, HUVEC with reduced Rab27a or controls were
exposed to lysosome or proteasome inhibitors. Chloroquine
(lysosome) completely rescued mVEGFR1 in Rab27a knockdown
HUVEC (Fig. 5g–i), while MG132 (proteasome) did not rescue
but significantly downregulated baseline mVEGFR1 levels
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(Supplementary Fig. 6g–i). These findings indicate that Rab27a
regulates mVEGFR1 protein levels by preventing lysosome-
mediated degradation of the receptor in endothelial cells.
We hypothesized that Rab27a-mediated mVEGFR1 stability
was linked to palmitoylation. To test this, we performed the
Acyl-RAC assay after incubating HUVEC with chloroquine to
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restore mVEGFR1 levels in the presence of reduced Rab27a levels.
Consistent with mis-localized DHHC3, mVEGFR1 capture was
significantly reduced in HUVEC with reduced Rab27a (Fig. 5j),
suggesting reduced palmitoylation. Collectively, these data show
that Rab27a regulates mVEGFR1 levels and suggest that it
functions through modulation of receptor palmitoylation, likely
via spatial regulation of DHHC3.
Rab27a is a negative regulator of angiogenesis. VEGFR1
negatively regulates blood vessel growth in vitro and in vivo,
but no regulatory function for Rab27a during angiogenesis has
been described. We hypothesized that Rab27a is anti-angiogenic
via its role in stabilizing mVEGFR1. Rab27a knockdown in
ex vivo mouse aortic rings53 significantly increased angiogenic
sprouting, although overall sprout length was not affected
(Fig. 6a–c). Rab27a knockdown in the sprouting angiogenesis
assay using HUVEC increased angiogenic sprouting and sprout
length, consistent with its hypothesized anti-angiogenic function
(Fig. 6d–f). Time course analysis showed that Rab27a knockdown
HUVEC had increased sprouts at all times, while Rab3a
knockdown did not affect angiogenic sprouting (Supplementary
Fig. 7a–d). Filopodia are thin, cellular actin-rich extensions
that sense the environment, influence endothelial cell migration
and are considered a hallmark of ‘active’ endothelium. Analysis
of Rab27a knockdown HUVEC sprouts also revealed a significant
increase in filopodia (Fig. 6g,h). Thus, knockdown of Rab27a
leads to increased HUVEC sprouting, suggesting a novel
anti-angiogenic function for Rab27a, likely through regulation
of mVEGFR1 stability.
Angiogenic effects of Rab27a are epistatic to VEGFR1. We
wondered whether Rab27a function is epistatic to mVEGFR1 in
sprouting angiogenesis. We found that reduced VEGFR1 levels
(Supplementary Fig. 7e) phenocopied the increased sprouting
seen in Rab27a knockdown sprouts, with no distinguishable
differences in sprout morphology or branching (Fig. 7a,b).
Because VEGFR1 negatively modulates signalling through
VEGFR2 (refs 21,54) and ERK activation is a downstream
effector of VEGFR2 signalling, we assessed pERK levels after
Rab27a knockdown in endothelial cells and found a significant
increase in both pERK and phosphorylated histone-H3, a mitosis
marker downstream of ERK activation (Fig. 7c, Supplementary
Fig. 7f,g).
We next asked whether exogenous addition of VEGFR1 altered
the effects of reduced Rab27a levels on sprouting angiogenesis,
using a truncated form of VEGFR1 linked to an FC domain
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(R1-FC), and found that the excess sprouting seen with reduced
Rab27a was significantly reduced by exogenous R1-FC (Fig. 7d,e).
These findings indicate that reduced Rab27a cannot overcome the
negative effects of exogenous VEGFR1 on sprouting and suggest
that they act through similar mechanisms. Further support for
this hypothesis is that R1-FC significantly blunted the elevated
pERK levels found in sprouts with reduced Rab27a (Fig. 7f,g). We
also observed increased pVEGFR2 in angiogenic sprouts with
reduced Rab27a (Fig. 7h,i), suggesting that increased ERK
activation in Rab27a knockdown sprouts is downstream of
elevated VEGFR2 signalling. Collectively, these results imply that
loss of mVEGFR1 downstream of Rab27a knockdown is required
for the effects of reduced Rab27a on angiogenesis, likely through
increased VEGFR2 signalling and activation of downstream
effector pathways.
Rab27a regulates FLT-1 levels and angiogenesis in vivo. Ashen
mice have a spontaneous point mutation in the rab27a
locus leading to loss-of-function55. Mice homozygous for
ashen (ash/ash) are viable and have several defects linked to
mis-trafficking, including defective melanosome trafficking
that leads to the ‘ash-like’ coat colour. We hypothesized that
blood vessels of ash/ash mice had angiogenic defects resulting
from destabilized FLT-1 (mouse VEGFR1). Ashenmice are on the
C3H/HeSn genetic background that also carries the rd mutation,
leading to retinal degeneration starting at 2–3 weeks of age56,57.
Thus we analysed post-natal retinal vessels that expand
via sprouting angiogenesis during the first week of life, prior
to photoreceptor cell degradation, and we compared all effects
to littermate controls that also carried the rd mutation. We found
detectable levels of Rab27a in vessels at the vascular front and in
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the vascular plexus behind the front in wild-type controls (þ /þ )
at post-natal day 6.5 (P6.5) that were dramatically reduced in
ash/ash homozygous littermates, along with undetectable levels of
Rab27a in ash/ash retinal lysates (P6.0) (Supplementary Fig. 8a,b).
Consistent with the hypothesis that loss of Rab27a destabilizes
VEGFR1 in vivo, post-natal (P5) retinal vessels of ash/ash
homozygous mice had significantly reduced levels of FLT-1
staining at the vascular front and in the plexus behind the
front compared to littermate controls (Fig. 8a–c). Examination of
vascular morphology showed significantly increased filopodia in
the plexus vessels and at the vascular front of ash/ash retinas
at P5, although overall sprout numbers were not affected
(Fig. 8d–g, inlay, red arrows). We also analysed later stages
(Supplementary Fig. 8c–h) and found that the increased filopodia
numbers were resolved at the vascular front by P6.5, but persisted
in the plexus vessels through P8.5. Consistent with these findings,
filopodia length was also increased in P8.5 retinas in the vascular
plexus but not at the vascular front (Supplementary Fig. 9a–c),
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suggesting that loss of Rab27a in retinal vessels results in an
initial hyperactive phenotype that perdures in the normally
more quiescent plexus behind the front with time. However,
vessel density was not increased in ash/ash mutant retinas at
P5.0–8.5 (Supplementary Fig. 9d–f), suggesting that hyperactivity
of ash/ash vessels leads to temporary morphogenetic changes
that are compensated in vivo.
We next asked whether the biochemical changes to VEGFR1 and
VEGF-A signalling components documented in vitro were seen
in vivo. We analysed retinal lysates and found reduced levels
of mFLT-1 at both P5.0 and P8.0 in ash/ash retinas compared to
wild-type littermate controls (Fig. 8h,i), consistent with the
hypothesis that mFLT-1 is destabilized with loss of Rab27a
in vivo. We performed the Acyl-RAC assay and found reduced
capture of mFLT-1 in p8.0 retinal lysates of ash/ash retinas
compared to controls (Fig. 8j, Supplementary Fig. 10), indicating
that mFLT-1 palmitoylation is compromised in vivo with loss of
Rab27a. The retinal lysates were also analysed for VEGF-A
signalling changes, and ash/ash retinas had elevated pFlk-1
and pERK relative to controls (Fig. 8k), suggesting that the
decoy function of mFLT-1 in VEGF-A signalling regulation is
compromised in vivo with loss of Rab27a. Collectively, these
findings show that Rab27a regulates FLT-1 levels during
angiogenesis in vivo, and reveal a vascular phenotype in ash/ash
mice that is consistent with destabilization of mFLT-1, presumably
via impaired palmitoylation and increased turnover of the receptor,
and increased VEGF-A signalling downstream of these effects.
Discussion
VEGFR1 regulates VEGF-A signalling amplitude via its decoy
function to control blood vessel growth and morphogenesis.
Unlike most receptors whose primary function is signalling,
membrane-localized VEGFR1 (mVEGFR1) is highly stable,
and its trafficking and turnover are exquisitely regulated via
post-translational palmitoylation. Disruption of this regulatory
axis affects angiogenesis in vitro and in vivo. We show that
mVEGFR1 palmitoylation regulates a switch from a stable,
constitutively recycling mode to a degradative route that is
predicted to remove ligands from the system. mVEGFR1 stability
and function requires proper trafficking of palmitoylation
enzymes, and Rab27a uniquely regulates angiogenesis via effects
on mVEGFR1 palmitoylation (Fig. 9). This new paradigm
shows that trafficking-dependent post-translational modifications
affecting decoy receptor stability regulate biological outputs, and
impact the fine-tuning of vascular processes in unexpected ways.
Protein half-lives vary by several orders of magnitude58. Short-
lived proteins are usually phosphorylation targets and signal, while
longer-lived proteins often function as ‘housekeeping’ proteins59.
The half-lives of VEGFR2 and VEGFR3 absent ligand are 70min
and 4h, respectively36,60, consistent with their primary function as
signalling receptors. In contrast, mVEGFR1 has a half-life greater
than 28h absent ligand. This stable pool of mVEGFR1
constitutively internalizes and likely recycles, allowing endothelial
cells to rapidly modulate VEGF-A signalling cell-autonomously,
without de novo protein synthesis. Other decoy receptors, such as
the atypical chemokine receptor D6, have an extended half-life and
also constitutively recycle61,62. mVEGFR1 trafficking and stability
depends on Rab11a, a small GTPase associated with the ‘slow’
recycling of proteins between endosomes and the cell surface,
similar to D6 (refs 63,64). Moreover, decoy receptors often traffic to
lysosomes upon ligand-binding, where ligand is released and
degraded while the receptor recycles, or the entire complex is
degraded63. These findings suggest that slow recycling and
extended stability are general features of negative modulators of
signalling, or molecular rheostats.
The reversibility of palmitoylation imparts versatility to protein
trafficking and stability. Insulin dynamically alters the endothelial
palmitoyl-proteome to influence angiogenesis in vitro30. We show
that mVEGFR1 stability is reversibly regulated by palmitoylation,
with unbound receptor palmitoylated and highly stable, while
ligand-bound receptor is destabilized in a palmitoylation-
dependent manner. VEGF-A binding to mVEGFR1 is predicted
to induce conformational changes65, and these changes may
induce depalmitoylation and mVEGFR1 trafficking to the
lysosome. Our finding that the stability and function of
mVEGFR1 depends on palmitoylation may represent a general
mechanism for stabilizing decoy receptors.
We identify a novel role for Rab27a in angiogenesis upstream
of mVEGFR1. Rab27a regulates mVEGFR1 palmitoylation and
stability, likely via its trafficking functions50,66. Consistent with
Rab27a affecting mVEGFR1 levels, Rab27a knockdown caused
mis-trafficking of the palmitoylation enzyme DHHC3, reduced
baseline palmitoylation and destabilized mVEGFR1, and elevated
VEGFR2 signalling in vitro and in vivo. Vascular sprouting in
3D assays and filopodia formation in vivo were increased by
loss or reduction of Rab27a, consistent with mis-regulation of
mVEGFR1 palmitoylation. Interestingly, mice homozygous for
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Figure 9 | Model for regulation of mVEGFR1 stability in endothelial cells. mVEGFR1 is normally (left) highly stable and slowly recycled to and from the
surface via Rab11a, requiring Rab27a and DHHC3 for palmitoylation; reduced Rab27a levels (right) destabilize mVEGFR1 via reduced palmitoylation, leading
to increased signalling through VEGFR2.
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/ncomms15699
12 NATURE COMMUNICATIONS | 8:15699 |DOI: 10.1038/ncomms15699 | www.nature.com/naturecommunications
ashen or lacking the cytoplasmic domain of mFLT-1 that is
presumably palmitoylated are viable20,55, suggesting compen-
sation mechanisms for destabilized mFLT-1 in vivo. However, the
reduced FLT-1 levels and vascular phenotype of ash/ash mutant
vessels are accompanied by increased VEGF-A signalling,
supporting that Rab27a regulates blood vessel formation
through effects on FLT-1 stability in vivo.
This new angiogenic regulatory axis influences mVEGFR1
stability and trafficking, and affects the responses of developing
vessels to environmental signals. Our work links palmitoylation
to VEGF-A signalling for the first time, and shows that
post-translational regulation of decoy receptors affects biological
outputs. Moreover, the likely mechanism of mVEGFR1
palmitoylation, via an enzyme that is trafficked and regulated
by Rab27a, suggests novel ways to manipulate and fine-tune
blood vessel morphogenesis.
Methods
Cell culture. No cell lines used in this study are found in the International Cell
Line Authentication Committee ICLAC commonly mis-identified cell line
database. HUVEC (Lonza, #2519A) were cultured in EBM-2 medium
supplemented with the bullet kit (EGM-2) (Lonza) and used at passages 3–5.
Normal human lung fibroblasts (NHLF) (Lonza, #CC-2512) were maintained in
DMEM supplemented with 10% newborn calf serum and used at passages 4–6. For
gene knockdown in HUVEC, approximately 1 106 cells were suspended in 100 ml
nucleofector solution (Lonza) before adding 50–150 pmol of siRNA (Silencer Select
Locked Nucleic Acids, Supplementary Table 3) and electroporating using the
A-034 program of the Amaxa Nucleofector system. For ligand stimulation,
HUVEC were starved in EBM-2 with 0.1% serum for 3 h, then 50 ngml 1 human
PLGF, VEGF-A or VEGF-B (Peprotech) was added. Recombinant human
VEGFR1-FC (R&D, # 321-FL-050) was polymerized in fibrin gels (25 ngml 1) for
3D sprouting assays. HUVEC and NHLF were certified mycoplasma-free by the
UNC Tissue Culture Facility.
Antibodies inhibitors and siRNAs. See Supplementary Tables 1–3 for antibodies,
inhibitors and siRNAs used for this study. HA-tagged DHHC3 was a kind gift of
Dr William Sessa (Yale University).
Mice. All experiments involving animals were performed with approval of the
University of North Carolina, Chapel Hill Institutional Animal Care and Use
Committee. Ashen mice (strain C3H/HeSn-Rab27aash/J) were purchased from
Jackson Laboratories (# 000120), bred in-house and used for experiments from
P5–P8.5. Male and female pups were used in equal proportions.
Retina dissection. Mouse retinas were processed as described67. Briefly, mice were
anaesthetized for 15min with isoflurane before being killed. Eyes were collected, fixed
in 4% paraformaldehyde (PFA) for 1 h, washed twice with PBS and then the retinas
dissected and stored in PBS at 4 C. Retinal lysates were generated by homogenizing
retinas using a microcentrifuge-tube pestle in the presence of 200ml RIPA with
2 protease/phosphatase inhibitor cocktail (Cell Signaling Technology). Ground
tissue was kept on ice and vortexed for 15 s every 5min for a total of 30min. Lysates
were centrifuged at 11,000g for 20min and supernatant transferred to a fresh tube.
Total protein was measured using the DC protein assay (Bio-Rad), and reduced and
denatured in Laemmli Buffer with 50mM DTT at 95 C for 20min.
Aortic ring assay. The aortic ring assay was carried out as described53. Briefly,
6-week-old male mice (C3H/HeSn) were anaesthetized with isofluorane for 5min
before being killed. The descending aorta was isolated, cleared of adventitia and placed
in serum-free Opti-MEM (Gibco) with 1 antibiotic/antimycotic (Gibco, 100 stock
solution). Aortas were sectioned intoB25 rings of 0.5mm thickness and placed in fresh
serum-free Opti-MEM with 1 antibiotic/antimycotic for 1h at 37 C. Rab27a-specific
siRNA or non-targeting control were diluted to 100nM in 480ml Opti-mem medium
containing 20ml Lipofectamine RNAi MAX (Invitrogen) and added to 4ml Opti-mem
and B30 rings for overnight incubation at 37 C. Rings were washed in PBS, and
embedded in 2.5mgml 1 fibrin supplemented with 37.5mlml 1 of 1mgml 1
aprotinin per ml of fibrinogen. EBM-2 medium supplemented with 0.2% FBS and
25ngml 1 VEGF-A was added to each well. Medium was changed on day 4, then
every other day.
Sprouting angiogenesis assay. The sprouting angiogenesis assay was performed
essentially as described37,68. Briefly, 5 106 HUVEC were trypsinized, mixed with
B2,000 pre-washed microcarrier beads (GE Healthcare) in 2ml EGM-2, incubated
for 4 h at 37 C with gentle flicking every 20min, then placed in EGM-2 overnight
at 37 C. On day 2, beads were transferred to 15ml tubes, allowed to settle and
medium was aspirated. After washing thrice in PBS, beads were suspended in
2mgml 1 fibrinogen solution (90% clottable) supplemented with 37.5 ml of
1mgml 1 aprotinin per ml of fibrinogen. Five hundred microlitres of solution was
added to each well of a glass-bottom 24-well plate containing 7 ml bovine thrombin
(50 units per ml). The solution was gently titrated three times, a fibrin clot was
formed for 3 h at 37 C, then NHLF were overlaid (B25,000 cells per well) in 1ml
EGM-2. The medium was changed 1 day later, then every other day.
Immunoblot. Immunoblot was performed as previously described69. Briefly,
cells were lysed in RIPA buffer containing protease/phosphatase inhibitor
(Cell Signaling), and approximately 20–50 mg of protein were separated by
SDS–PAGE and transferred to PVDF membranes. Membranes were blocked for
30min in 5% milk in PBS supplemented with 0.1% Tween-20 (PBS-T), and
incubated at 4 C with primary antibodies in 1% non-fat milk in PBS-T overnight
(Supplementary Table 1). Membranes were washed thrice in PBS-T (PBSþ 0.1%
Tween-20) before adding HRP-conjugated secondary antibodies for 1 h at RT.
Secondary antibody was removed and membranes washed four times in
PBS-T before addition of Luminata Forte (Millipore). For subcellular
fractionations, sequential lysing was carried using the Cell Fractionation Kit
(Cell Signaling #9038), according to the manufacturer’s protocol, before running
lysates on SDS–PAGE and blotting.
HUVEC immunofluorescence. Coverslips were prepared by washing in 100%
ethanol, followed by passing the coverslip through a flame and then storing in
100% ethanol. Before seeding cells, coverslips were washed in PBS and overlaid
with 0.1% gelatin for 15min. Before imaging, cells were washed twice with PBS,
fixed in 4% PFA for 10min at RT and permeabilized with 0.5% Triton X-100 for
5min. Blocking was performed for 30min at RT in a solution in PBS supplemented
with 5% goat serum, 2% BSA and 0.1% Tween-20 (staining solution) before
addition of antibody (Supplementary Table 1) overnight at 4 C. The next day, cells
were washed five times with PBS-T and incubated with Alexa-fluor-conjugated
anti-species secondary (1:1,000) for 1 h at RT. Cells were then washed five times
with PBS-T and incubated with Alexa-fluor-conjugated phallodin (1:500) and
DRAQ7 (1:1,000) in PBS for 30min to visualize F-actin and nuclei, respectively.
Coverslips were mounted to slides using Fluorogel inTris buffer (Electron
Microscopy Sciences) and sealed with nail polish.
HUVEC sprout immunofluorescence. Fibroblasts were removed using 0.25%
trypsin for B1min, and fibrin gels washed thrice with PBS. Gels were fixed with
4% PFA for 30min, then permeabilized using 0.5% Triton X-100 in PBS for 1 h at
RT. Wells were washed in PBS and fixed with 4% PFA in PBS for 30min. Sprouts
were permeabilized with 0.5% Triton X-100, washed thrice with PBS, blocked in
staining solution for 3 h at RT (see previous section), then incubated with primary
antibody at 4 C for 48 h (Supplementary Table 1). Gels were washed for 24 h with
0.5% Tween-20 and incubated with Alexa fluor-conjugated secondary for 4 h at RT.
Gels were washed 5 20min with 0.5% Tween-20 and incubated overnight at 4 C
with phalloidin (1:200) or DRAQ7 (1:1,000) in PBS.
Aortic ring immunofluorescence. Staining of mouse aortic rings was performed
essentially as described53, and as indicated above, with a few exceptions. Rings were
fixed with 4% PFA for 1 h at RT, then permeabilized in 1% Triton X-100 for 45min
at RT. Rings were blocked in 2% BSA/5% goat serum/0.5% Tween-20 overnight at
4 C, then incubated with primary antibody/secondary antibody as described
above. Before imaging, rings were incubated with Alexa-fluor 488 conjugated
isolectin (1:100) for 1 h at RT.
Retina immunofluorescence. Retinas were dissected, cleaned and dehydrated in
100% ethanol for 30min followed by permeabilization with 1% Triton X-100 for
30min at RT. Retinas were blocked in retina staining solution (5% goat serum, 1%
BSA, 1% Triton X-100) for 3 h at RT, followed by overnight incubation with
primary antibody at 4 C. Retinas were washed four times with 0.5% triton X-100,
followed by incubation with Alexa fluor-conjugated secondary antibody for 3 h at
RT. Retinas were washed four times, counterstained with isolectin (1:100) at 4 C
overnight, and mounted using fluoro-gel.
Internalization assays. Internalization assays were performed essentially as
described38, with slight modification. For VEGFR1 internalization, HUVEC were
washed five times with pre-chilled PBS supplemented with Caþ 2 and Mgþ 2
(PBSþ ) on ice at 4 C. Following washing, HUVEC were incubated with ice-cold
blocking/internalization solution EBM-2 supplemented with 0.5% w/v BSA for
30min on ice at 4 C to prevent internalization. Alexa-fluor-488 conjugated
primary antibody against VEGFR1 (Abcam Cat # 195253) or IgG isotype control
(Cell Signaling Technologies Cat t# 4340) was added (1:50) to pre-chilled blocking
solution incubated with HUVEC for 2 h at 4 C to label cell surface proteins. After
2 h, cells were washed five times in ice cold PBSþ before adding pre-warmed
(37 C) internalization medium to each plate and incubating at 37 C for 45min to
activate endocytosis. When striping of the cell surface was performed, HUVEC
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were incubated with 0.5 NaCl/0.2M acetic acid for 4min after internalization but
before fixation to remove antibody from cell surface receptors.
Cell surface protein isolation. Biotinylation and isolation of cell surface proteins was
performed according to the manufacturer’s protocol (Cell Surface Protein Isolation Kit,
Pierce cat# 89881). Briefly, control and 2-BH-treated HUVEC (see Supplementary
Table 2) were washed twice in 10ml of ice-cold PBS to stop internalization and
incubated with EZ-link Sulfo-NHS-SS-Biotin at 4 C for 30min with constant rocking.
HUVEC were washed twice with ice-cold PBS and removed from the plate by gently
scraping. After centrifugation at 500g for 3min, cells were lysed using provided lysis
buffer supplemented with 1 protease/phosphatase inhibitors (Cell Signaling
Technologies). Biotinylated proteins were captured using NeutrAvidin Agarose
slurry-containing spin columns. Flow-through was saved for analysis, and the column
was eluted with 1M DTT. Total protein from the eluate (labelled proteins) and flow
through (unlabeled proteins) were analysed by immunoblot.
Acyl biotin exchange assay. Acyl Biotin Exchange was performed essentially as
described43. Semi-confluent HUVEC were pooled, lysed on ice in 1% IGEPAL
dissolved in (50mM Tris-HCL pH 7.5, 150mM NaCL, 10% glycerol with PMSF
and protease/phosphatase inhibitor) for 30min in the presence of 10mM
N-ethylmaleimide (NEM) to block free cysteines. Lysates were cleared by
centrifugation (16,000g for 30min). Five micrograms of aVEGFR1 antibody and
fresh NEM was added to the supernatant and incubated overnight at 4 C. The
following day, 100ml protein A/G agarose beads were added to the solution and
rotated for 2 h at 4 C to precipitate VEGFR1. After centrifugation (0.5g), beads were
resuspended in 600ml lysis buffer containing 10mM NEM and split to input, minus
hydroxylamine (HAM) and plus (þHAM) conditions before washing with lysis
buffer containing 0.1% SDS. Beads were resuspended in lysis bufferþ 1M HAM
(or molar equivalent of NaCl for negative control) and rotated for 2 h at 37 C. Beads
were centrifuged and washed thrice in lysis buffer with 10mM NEM. Biotin-BMCC
was freshly prepared in DMSO and added to a final concentration of 2.0mM in lysis
buffer, and samples were rotated for 1 h at 4 C. Beads were washed thrice in lysis
buffer containing protease/phosphate inhibitors, and VEGFR1 was eluted from beads
by addition of Laemmli sample buffer with 100mM DTT at 90 C for 20min. Input,
HAM and þHAM conditions were analysed by immunoblot using streptavidin-
HRP, then stripped and re-probed with VEGFR1 antibody.
Acyl resin-assisted capture (Acyl-RAC) assay. Acyl resin-assisted capture
was performed as described42. For 2-BH experiments, semi-confluent HUVEC
were treated with 5 mM 2-BH or EtOH for 12 h to block palmitoylation. For
Rab27a knockdown experiments, HUVEC were transfected with 100 pmol of
Rab27a-specific or non-targeting control siRNA (see cell culture section for details)
2 days before the experiment. Non-targeting controls and siRab27a-transfected
HUVEC were incubated with 10 mgml 1 chloroquine for 2 h at 37 C. After
experimental manipulations, HUVEC were mechanically scraped from the dish in
ice cold PBS and pelleted by centrifugation at 200g for 10min at 4 C. PBS was
removed and the pellets suspended in 200 ml lysis buffer (25mM HEPES, 25mM
NaCl, 1mM EDTA, 0.5% Triton X-100, pH 7.5) with protease/phosphatase
inhibitors on ice for 30min. Whole retinas were lysed in RIPA (see above) with
2 protease phosphatase inhibitors using a tube pestle. Lysates were centrifuged at
11,000g for 20min, and the supernatants were collected for further processing.
Equal amounts of protein from each sample were diluted to 2mgml 1 in blocking
buffer (100mM HEPES, 1.0mM EDTA, 2.5% SDS, pH 7.5) containing 0.1%
methanethiosulfonate and incubated at 40 C for 12min, with vortexing every
2min, to irreversibly block free cysteines. Proteins were precipitated by adding
3-volumes of 100% ice cold acetone and incubating at  20 C for 30min, then
centrifuging at 5,000g for 10min. Protein pellets were washed thrice with 70%
acetone, dried and re-suspended in 300 ml binding buffer (100mM HEPES, 1.0mM
EDTA, 1% SDS, pH 7.5) containing protease/phosphatase inhibitors. Twenty
microlitres of solution was set aside for input control. Fifty microlitres pre-washed
thiopropyl sepharose 6B (Sigma cat # T8387) was added to each sample, followed
by addition of 40ml of 2M HAM (pH 7.5) (þHAM condition) or 40ml of 2M
NaCl (HAM condition). Samples were rotated at 37 C for 2 h. Thiopropyl
sepharose beads were washed four times in binding buffer, and captured proteins
were eluted from the beads by addition of 50mM DTT in 50 ml binding buffer for
20min. Eluted proteins were then boiled at 90 C for 20min in Laemmli sample
buffer (375mM Tris-HCL pH 6.8, 9% w/v SDS, 50% glycerol, 0.03% bromophenol
blue, 100mM DTT) and analysed by immunoblot.
Imaging. All imaging was done using an Olympus FV1200 Laser Scanning
Confocal Microscope (60 oil objective with 1.4 NA or 40 silicone objective
with 1.25 NA) and Flow View software.
Image and statistical analysis. Priori power analysis determined a minimum
sample size of 5 pups per group (alpha 0.05, effect size 20%) for 90% power when
calculating differences in retinal vessel area and plexus filopodia. All quantifications
were measured and analysed by a blinded researcher. For quantitative
immunofluorescence image analysis, corrected total cell fluorescence was calculated
for individual cells using integrated density (mean fluorescence of the area  cell
area) (http://fiji.sc/). Normalized data sets were graphed and analysed using
PRISM. For two-sample data sets with equal variances (control versus a single
experimental condition) unpaired, two-tailed Student’s t-test was used as reported
in figure legends. For data sets with greater than two conditions and equal
variances, one-way ANOVA with Tukey’s post-hoc test was used as reported in the
figure legends. *Pr0.05, **Pr0.01, ***Pr0.001, ns, not significant.
Data availability. All data in support of the findings of this work can be found
within the article and its Supplementary Information, and from the corresponding
author on reasonable request.
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